Arrowhead doses first patient in Part B of Phase I trial of ARC-AAT to treat AATD

US-based Arrowhead Research has dosed the first patient in Part B of a Phase I clinical trial of its RNAi-based drug candidate ARC-AAT to treat liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news